What is the main purpose of extending these Change in Control Agreements?

The primary purpose of extending these agreements is typically to ensure the retention of key executive talent. By providing financial security and defined benefits in the event of a change in control, Abbott aims to mitigate potential leadership departures during uncertain periods and maintain executive focus on long-term company performance.

Why is Miles D. White excluded from this extension?

Miles D. White, as Chairman and CEO, is not party to these specific Change in Control Agreements. His executive compensation and protections are likely governed by separate arrangements or employment terms that do not fall under these particular 'Agreements Regarding Change in Control' that were extended.

What constitutes a 'Change in Control' under these agreements?

While this 8-K filing does not detail the specific triggers for a 'Change in Control', these types of agreements generally define such events to include scenarios like a merger, acquisition, significant change in board composition, or sale of substantially all company assets. The exact definition would be outlined in the full text of the agreements.

Does this extension imply an imminent change in control for Abbott?

Not necessarily. Extending these agreements is a proactive measure common in corporate governance. It signals Abbott's commitment to leadership stability and executive retention, but it does not confirm that a change in control event is currently underway or anticipated.

ABT 8-K: Leadership Changes

Summary

Abbott Laboratories (ABT) filed an 8-K report on November 16, 2016, to disclose an update regarding its Change in Control Agreements with named executive officers. These agreements, which were set to expire on December 31, 2016, have had their terms extended for an additional two years, now concluding on December 31, 2018. This extension applies to all named executive officers except for Chairman and CEO Miles D. White, who is not a party to such an agreement. This action signals a continued commitment to retaining key leadership by providing them with enhanced security and compensation terms during potential periods of uncertainty or transition within the company.

Key Highlights

1Abbott Laboratories has extended the term of its Change in Control Agreements for named executive officers.
2The agreements were extended for two years, from December 31, 2016, to December 31, 2018.
3This extension applies to named executive officers, excluding Chairman and CEO Miles D. White.
4The Change in Control Agreements provide benefits to executives in the event of specific changes within the company.
5The filing was made on November 16, 2016, with an event date of November 15, 2016.
6The purpose of such agreements is often to ensure executive retention and stability, particularly during times of potential corporate change.

ABBOTT LABORATORIES 8-K Report, Executive Changes (Nov 16, 2016)

Summary

Key Highlights

Frequently Asked Questions